Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Media
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • ACT Tulsa
  • Contact

i2E leads $1.4M investment in Synereca

    Home Entrepreneur i2E leads $1.4M investment in Synereca
    NextPrevious

    i2E leads $1.4M investment in Synereca

    By admin | Entrepreneur, News, SeedStep Angels, Uncategorized | Comments are Closed | 9 September, 2014 | 0

    September 9, 2014

    Company focused on developing compounds to kill antibiotic-resistant bacteria

    Contact: Sarah Seagraves,
    Senior VP for Marketing
    (405) 813-2403
    or email sseagraves@i2E.org

    i2E, Inc., recently closed on a $1.4 million seed capital investment in Oklahoma City-based Synereca Pharmaceuticals, which is developing ground-breaking compound that kills drug resistant bacteria.

    The investment was led by the i2E-managed Oklahoma Seed Capital Fund and Accele Venture Partners with participation by the SeedStep Angels group, also managed by i2E, as well as by Oklahoma Angel investors.

    With research laboratories in Oklahoma City and Chapel Hill, N.C., Synereca Pharmaceuticals is pursuing development of inhibitors that overcome and prevent the growing bacterial resistance to antibiotics.

    “We’ve demonstrated that we have a compounds that without shifting toxicity make antibiotics more effective,” said Clayton Duncan, Synereca CEO.  “We’re going to use this investment to try to advance that set of compounds to improve the efficacy of the Colistin, an older antibiotic, against difficult to treat multidrug resistant bacteria. Over 90 percent of these investment dollars will go to research.”

    Accele Venture Partners, LP, is a limited partnership formed to invest, together with established institutional life science investors, in the initial funding of life science companies selected and managed by Accele Biopharma, Inc.

    The Oklahoma Seed Capital Fund is a state-appropriated investment fund through the Oklahoma Center for the Advancement of Science and Technology.

    The SeedStep Angels group was founded by i2E in 2009 and is now the state’s largest angel investment group with more than 40 members and chapters in Oklahoma City, Tulsa, Ardmore and Muskogee.

    About Synereca Pharmaceuticals

    Management: Clayton Duncan, CEO; Richard Gammans, Ph.D., Chief Operation Officer; Scott Singleton, Ph.D., Chief Scientific Officer

    Year Started: 2009

    Location: Oklahoma City, OK and Chapel Hill, NC

    Synereca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing drugs that restore or increase the effectiveness of existing antibiotics.  Synereca’s development program focuses on inhibiting “RecA,” a key enzyme in bacterial DNA repair and the development and transmission of antibiotic resistance.

    About i2E, Inc.:  With offices in Oklahoma City and Tulsa, OK, i2E’s nationally recognized services include business expertise and funding for Oklahoma’s emerging small businesses. i2E has more than $40 million of investment capital under management.

    ###

     

     

     

    Accele Venture Partners, Oklahoma Seed Capital Fund, SeedStep Angels, Synereca Pharmaceuticals

    NextPrevious
    i2E-300dpi-Trans-Light
    • Events
    • News
    • Resources
    • Media
    • Love’s Cup

    Oklahoma City Office

    840 Research Parkway, Suite 250
    OKC, OK 73104
    PHONE 405/235-2305
    Click HERE for printable map with directions.

    Tulsa Office

    100 S. Cincinnati Ave – 5th Floor, Suite 514
    Tulsa, OK 74103
    PHONE 918/582-5592
    Copyright 2022 i2E, Inc. | All Rights Reserved
    • About
    • Entrepreneurship
      • Venture Advisory Services
      • Love’s Entrepreneur’s Cup
      • ACT Tulsa
    • e3
    • Concept Fund
    • Portfolio
    • iMCI
    • ACT Tulsa
    • Contact
    i2E